Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 49 |
| Active Pipeline (Recruiting Now) | 10 (6) |
| Completed vs Stopped Early | 26 / 13 (26.5%) |
| Median Closed Actual Enrollment | 24 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of North Carolina at Chapel Hill | Chapel Hill, NC | 7 |
| University of North Carolina | Chapel Hill, NC | 6 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06636786 | Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UNC Health across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the University of North Carolina, Chapel Hill Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.